1. Home
  2. ALLO vs BWAY Comparison

ALLO vs BWAY Comparison

Compare ALLO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • BWAY
  • Stock Information
  • Founded
  • ALLO 2017
  • BWAY 2003
  • Country
  • ALLO United States
  • BWAY Israel
  • Employees
  • ALLO N/A
  • BWAY N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • BWAY Medical/Dental Instruments
  • Sector
  • ALLO Health Care
  • BWAY Health Care
  • Exchange
  • ALLO Nasdaq
  • BWAY Nasdaq
  • Market Cap
  • ALLO 252.9M
  • BWAY 280.7M
  • IPO Year
  • ALLO 2018
  • BWAY 2019
  • Fundamental
  • Price
  • ALLO $1.27
  • BWAY $15.17
  • Analyst Decision
  • ALLO Buy
  • BWAY Strong Buy
  • Analyst Count
  • ALLO 11
  • BWAY 2
  • Target Price
  • ALLO $8.67
  • BWAY $20.50
  • AVG Volume (30 Days)
  • ALLO 2.3M
  • BWAY 68.1K
  • Earning Date
  • ALLO 11-06-2025
  • BWAY 11-11-2025
  • Dividend Yield
  • ALLO N/A
  • BWAY N/A
  • EPS Growth
  • ALLO N/A
  • BWAY 213.09
  • EPS
  • ALLO N/A
  • BWAY 0.13
  • Revenue
  • ALLO N/A
  • BWAY $49,094,000.00
  • Revenue This Year
  • ALLO N/A
  • BWAY N/A
  • Revenue Next Year
  • ALLO $100.00
  • BWAY N/A
  • P/E Ratio
  • ALLO N/A
  • BWAY $46.38
  • Revenue Growth
  • ALLO N/A
  • BWAY 27.08
  • 52 Week Low
  • ALLO $0.86
  • BWAY $7.84
  • 52 Week High
  • ALLO $3.78
  • BWAY $17.92
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 53.43
  • BWAY 42.95
  • Support Level
  • ALLO $1.16
  • BWAY $14.72
  • Resistance Level
  • ALLO $1.28
  • BWAY $16.63
  • Average True Range (ATR)
  • ALLO 0.09
  • BWAY 0.69
  • MACD
  • ALLO 0.01
  • BWAY -0.19
  • Stochastic Oscillator
  • ALLO 70.68
  • BWAY 11.72

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: